These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32028998)

  • 1. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
    Bellomo R; Wunderink RG; Szerlip H; English SW; Busse LW; Deane AM; Khanna AK; McCurdy MT; Ostermann M; Young PJ; Handisides DR; Chawla LS; Tidmarsh GF; Albertson TE
    Crit Care; 2020 Feb; 24(1):43. PubMed ID: 32028998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
    Bellomo R; Forni LG; Busse LW; McCurdy MT; Ham KR; Boldt DW; Hästbacka J; Khanna AK; Albertson TE; Tumlin J; Storey K; Handisides D; Tidmarsh GF; Chawla LS; Ostermann M
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1253-1261. PubMed ID: 32609011
    [No Abstract]   [Full Text] [Related]  

  • 3. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
    Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
    Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
    Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
    Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.
    Wang K; Basu R; Poglitsch M; Bakal JA; Oudit GY
    Circ Heart Fail; 2020 Jul; 13(7):e006939. PubMed ID: 32580658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
    N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock.
    Leisman DE; Handisides DR; Chawla LS; Albertson TE; Busse LW; Boldt DW; Deane AM; Gong MN; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Thompson BT; Tumlin JS; Adams CD; Hodges TN; Bellomo R
    Ann Intensive Care; 2023 Dec; 13(1):128. PubMed ID: 38103056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the norepinephrine to angiotensin II conversion ratio in patients with vasodilatory hypotension: A post-hoc analysis of the ARAMIS trial.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    J Crit Care; 2024 Feb; 79():154453. PubMed ID: 37890357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of gender and genetic variability on plasma angiotensin peptides.
    Reyes-Engel A; Morcillo L; Aranda FJ; Ruiz M; Gaitan MJ; Mayor-Olea A; Aranda P; Ferrario CM
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):92-7. PubMed ID: 17083063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries.
    Wang K; Gheblawi M; Nikhanj A; Munan M; MacIntyre E; O'Neil C; Poglitsch M; Colombo D; Del Nonno F; Kassiri Z; Sligl W; Oudit GY
    Hypertension; 2022 Feb; 79(2):365-378. PubMed ID: 34844421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series.
    Tezel O; Hutson TK; Gist KM; Chima RS; Goldstein SL; Stanski NL
    Crit Care Explor; 2023 Sep; 5(9):e0978. PubMed ID: 37711646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.
    Hisatake S; Kiuchi S; Kabuki T; Oka T; Dobashi S; Ikeda T
    Heart Vessels; 2017 Mar; 32(3):303-308. PubMed ID: 27421979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review.
    Semedi BP; Rehatta NM; Soetjipto S; Nugraha J; Mahyuddin MH; Arnindita JN; Wairooy NAP
    Open Access Emerg Med; 2023; 15():1-11. PubMed ID: 36636460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
    Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
    J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Active Renin Content With Mortality in Critically Ill Patients: A Post hoc Analysis of the Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) Trial.
    Busse LW; Schaich CL; Chappell MC; McCurdy MT; Staples EM; Ten Lohuis CC; Hinson JS; Sevransky JE; Rothman RE; Wright DW; Martin GS; Khanna AK;
    Crit Care Med; 2024 Mar; 52(3):441-451. PubMed ID: 37947484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower circulating levels of angiotensin-converting enzyme (ACE) in patients with schizophrenia.
    Mohite S; de Campos-Carli SM; Rocha NP; Sharma S; Miranda AS; Barbosa IG; Salgado JV; Simoes-E-Silva AC; Teixeira AL
    Schizophr Res; 2018 Dec; 202():50-54. PubMed ID: 29925475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue.
    Campbell DJ; Duncan AM; Kladis A
    Hypertension; 1999 Aug; 34(2):171-5. PubMed ID: 10454436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular control via angiotensin II and circulating catecholamines in the spiny dogfish, Squalus acanthias.
    Bernier NJ; Gilmour KM; Takei Y; Perry SF
    J Comp Physiol B; 1999 Jul; 169(4-5):237-48. PubMed ID: 10466217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.
    Dell'Italia LJ; Meng QC; Balcells E; Wei CC; Palmer R; Hageman GR; Durand J; Hankes GH; Oparil S
    J Clin Invest; 1997 Jul; 100(2):253-8. PubMed ID: 9218500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.